PURPOSE: The objective of the study was to describe the occurrence of @entity3136 and @entity358 in @entity1 with @entity1358 ( @entity1358 ) treated with second-line @entity2239 in a real-world setting. METHODS: This multicenter, prospective, observational study was conducted in France by physicians with experience of treatment of @entity1 with @entity1358 . @entity1 aged >= 18  years who received @entity2239 after first-line antivascular endothelial growth factor ( @entity7 ) therapy were included in the study. The primary safety assessments were occurrence of @entity3136 (in terms of severity, event dates, and therapeutic management) and noninfectious @entity55 (in terms of detection methodology, severity, event dates, and therapeutic management). RESULTS: Between September 2010 and August 2012, 284 @entity1 were enrolled at 77 centers, of whom, 274 received @entity2239 therapy. Most @entity1 had @entity1358 of clear cell histology (88%), and most of them (84%) received first-line @entity2240 . In total, 40% of @entity1 experienced treatment-related @entity3136 , and 15% of @entity1 experienced @entity358 . Most of them had a single episode. The incidence of grade 3 @entity3136 and @entity358 were 8 and 3%, respectively. Mean time to the first episode was 27  days for @entity3136 and 72  days for @entity358 from treatment initiation. @entity3136 and @entity358 resulted in treatment discontinuations in 2 and 7% of @entity1 , respectively. The primary first-episode treatment was mouthwash (86%) for @entity3136 and corticosteroids (65%) for @entity358 . CONCLUSIONS: This study confirms that @entity3136 and @entity358 are commonly associated with @entity2239 use. Both adverse events were rarely severe and were managed easily and efficiently.

A prospective observational study on the evaluation of @entity2239 -related adverse events in @entity1358 after first-line anti- XXXX therapy: the AFINITE study in France.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity3136 :: ('MESH:D013280', 'Disease') :: ['stomatitis', 'Stomatitis'] @entity2240 :: ('MESH:C473478', 'Chemical') :: ['sunitinib'] @entity7 :: ('7422', 'Gene') :: ['VEGF'] @entity55 :: ('MESH:D011014', 'Disease') :: ['pneumonitis'] @entity2239 :: ('MESH:C107135', 'Chemical') :: ['everolimus'] @entity1358 :: ('MESH:D002292', 'Disease') :: ['mRCC', 'metastatic renal cell carcinoma'] @entity358 :: ('MESH:D008171', 'Disease') :: ['noninfectious lung disease']
@entity7 :: (7422,Gene) :: ['vascular endothelial growth factor']
